The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Thrombin Responses in Human Endothelial Cells
Open accessAbstract
The recent identification of two new thrombin receptors, PAR3 and PAR4, led us to re-examine the basis for endothelial cell responses to thrombin. Human umbilical vein endothelial cells (HUVEC) are known to express PAR1 and the trypsin/tryptase receptor, PAR2. Northern blots detected both of those receptors and, to a lesser extent, PAR3, but PAR4 message was undetectable and there was no response to PAR4 agonist peptides. To determine whether PAR3 or any other receptor contributes to thrombin signaling in HUVEC, PAR1 cleavage was blocked with two selective antibodies and PAR1 activation was inhibited with the antagonist, BMS200261. The antibodies completely inhibited HUVEC responses to thrombin, but BMS200261 was only partly effective, even though separate studies established that the antagonist completely inhibits PAR1 signaling at the concentrations used. Since peptides mimicking the PAR1 tethered ligand domain can also activate PAR2, we asked whether the remaining thrombin response in the presence of the antagonist could be due in part to the intermolecular transactivation of PAR2 by cleaved PAR1. Evidence that transactivation can occur was obtained in COS-7 cells co-expressing PAR2 and a variant of PAR1 that can be cleaved, but not signal. There was a substantial response to thrombin only in cells expressing both receptors. Conversely, in HUVEC, complete blockade of the thrombin response by the PAR1 antagonist occurred only when signaling through PAR2 was also blocked. From these observations we conclude that 1) PAR1 is the predominant thrombin receptor expressed in HUVEC and cleavage of PAR1 is required for endothelial cell responses to thrombin; 2) although PAR3 may be expressed, there is still no evidence that it mediates thrombin responses; 3) PAR4 is not expressed on HUVEC; and 4) transactivation of PAR2 by cleaved PAR1 can contribute to endothelial cell responses to thrombin, particularly when signaling through PAR1 is blocked. Such transactivation may limit the effectiveness of PAR1 antagonists, which compete with the tethered ligand domain rather than preventing PAR1 cleavage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Cloning: A Laboratory Manual
Sambrook, J., Fritsch, E., & Maniatis, T. (1989) · UCLA - Biblioteca de Ciencias de la Salud · Cited by 133,589
Molecular Cloning. A Laboratory Manual
Wood, E. (1983) · Biochemical Education · doi:10.1016/0307-4412(83)90068-7 · Cited by 29,533
Inositol trisphosphate and calcium signalling
Berridge, M. J. (1993) · Nature · doi:10.1038/361315a0 · Cited by 6,545
Vu, T.-K. H., Hung, D. T., Wheaton, V. I., & Coughlin, S. R. (1991) · Cell · doi:10.1016/0092-8674(91)90261-v · Cited by 2,970
Okamoto, T., Schlegel, A., Scherer, P. E., & Lisanti, M. P. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.10.5419 · Cited by 1,498
G-protein-coupled receptor heterodimerization modulates receptor function
Jordan, B. A., & Devi, L. A. (1999) · Nature · doi:10.1038/21441 · Cited by 1,166
A dual thrombin receptor system for platelet activation
Kahn, M. L., Zheng, Y.-W., Huang, W., Bigornia, V., Zeng, D., Moff, S., Farese, R. V., Tam, C., & Coughlin, S. R. (1998) · Nature · doi:10.1038/29325 · Cited by 979
Molecular cloning of a potential proteinase activated receptor.
Nystedt, S., Emilsson, K., Wahlestedt, C., & Sundelin, J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.20.9208 · Cited by 886
Protease-activated receptor 3 is a second thrombin receptor in humans
Ishihara, H., Connolly, A. J., Zeng, D., Kahn, M. L., Wu Zheng, Y., Timmons, C., Tram, T., & Coughlin, S. R. (1997) · Nature · doi:10.1038/386502a0 · Cited by 865
Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin
Kahn, M. L., Nakanishi-Matsui, M., Shapiro, M. J., Ishihara, H., & Coughlin, S. R. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6042 · Cited by 841
Cited by
Thrombin signalling and protease-activated receptors
Coughlin, S. R. (2000) · Nature · doi:10.1038/35025229 · Cited by 2,482
Proteinase-activated Receptors
(2006) · Encyclopedic Reference of Molecular Pharmacology · doi:10.1007/3-540-29832-0_1335 · Cited by 1,137
New Fundamentals in Hemostasis
Versteeg, H. H., Heemskerk, J. W. M., Levi, M., & Reitsma, P. H. (2013) · Physiological Reviews · doi:10.1152/physrev.00016.2011 · Cited by 1,126
Protease-Activated Receptors: Contribution to Physiology and Disease
OSSOVSKAYA, V. S., & BUNNETT, N. W. (2004) · Physiological Reviews · doi:10.1152/physrev.00028.2003 · Cited by 1,078
Protease‐activated receptors in hemostasis, thrombosis and vascular biology
COUGHLIN, S. R. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01377.x · Cited by 1,035
Endothelial cell control of thrombosis
Yau, J. W., Teoh, H., & Verma, S. (2015) · BMC Cardiovascular Disorders · doi:10.1186/s12872-015-0124-z · Cited by 691
Feistritzer, C., & Riewald, M. (2005) · Blood · doi:10.1182/blood-2004-10-3985 · Cited by 475
International Union of Pharmacology. XXVIII. Proteinase-Activated Receptors
Hollenberg, M. D., & Compton, S. J. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.203 · Cited by 442
Heuberger, D. M., & Schuepbach, R. A. (2019) · Thrombosis Journal · doi:10.1186/s12959-019-0194-8 · Cited by 371
Structure, function and pathophysiology of protease activated receptors
Adams, M. N., Ramachandran, R., Yau, M.-K., Suen, J. Y., Fairlie, D. P., Hollenberg, M. D., & Hooper, J. D. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.003 · Cited by 370
Inhibition of tissue factor signaling suppresses tumor growth
Versteeg, H. H., Schaffner, F., Kerver, M., Petersen, H. H., Ahamed, J., Felding-Habermann, B., Takada, Y., Mueller, B. M., & Ruf, W. (2008) · Blood · doi:10.1182/blood-2007-07-101048 · Cited by 327
Targeting proteinase-activated receptors: therapeutic potential and challenges
Ramachandran, R., Noorbakhsh, F., DeFea, K., & Hollenberg, M. D. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3615 · Cited by 312
Mechanistic coupling of protease signaling and initiation of coagulation by tissue factor
Riewald, M., & Ruf, W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141126698 · Cited by 306
Signal transduction by protease‐activated receptors
Soh, U. J., Dores, M. R., Chen, B., & Trejo, J. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00705.x · Cited by 294
Protease-activated receptor 2 signaling in inflammation
Rothmeier, A. S., & Ruf, W. (2012) · Seminars in Immunopathology · doi:10.1007/s00281-011-0289-1 · Cited by 289
Hepatic microcirculation and mechanisms of portal hypertension
Gracia-Sancho, J., Marrone, G., & Fernández-Iglesias, A. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0097-3 · Cited by 274
G protein-coupled receptor heteromers
Gomes, I., Ayoub, M. A., Fujita, W., Jaeger, W. C., Pfleger, K. D. G., & Devi, L. A. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135952 · Cited by 262
Tissue factor as a link between inflammation and coagulation
Witkowski, M., Landmesser, U., & Rauch, U. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2015.12.001 · Cited by 240
“[56] O'Brien PJ, Prevost N, Molino M, Hollinger MK, Woolkalis MJ, Woulfe DS, et al.”
Background
Metadata
- Authors
- O'Brien, P. J., Prevost, N., Molino, M., Hollinger, M. K., Woolkalis, M. J., Woulfe, D. S., & Brass, L. F.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2000-05
- Volume
- 275
- Issue
- 18
- Pages
- 13502-13509
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2081971657
- Cited by
- 297
- References
- 40
- FWCI
- 8.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.